

MDS
Azacitidine

Height	cm
Weight	kg
BSA	m ²

Cycle length:	28 days
Cycle no	
Destination	

CBC		Limits
Date		
Hb		
Neuts		
Plts		

Hypersensitivities/Allergies

Give outpatient prescription for:
Ondansetron 8mg PO daily
Domperidone 10mg PO QID PRN

Agent	Round
Azacitidine	10mg

DOSE MODIFIED: No Yes

Reference: RM Lyons, et al. J Clin Oncol. 2009;27:1850-1856

Day	Date	Time	Agent	Dose	Route	Instructions	Doctor	Nurse	Check	Start	Stop
1			Azacitidine 75mg/m ²	mg	SC	Slow push. If > 4mL split dose & inject at 2 separate sites.					
2			Azacitidine 75mg/m ²	mg	SC	Slow push. If > 4mL split dose & inject at 2 separate sites.					
3			Azacitidine 75mg/m ²	mg	SC	Slow push. If > 4mL split dose & inject at 2 separate sites.					
4			Azacitidine 75mg/m ²	mg	SC	Slow push. If > 4mL split dose & inject at 2 separate sites.					
5			Azacitidine 75mg/m ²	mg	SC	Slow push. If > 4mL split dose & inject at 2 separate sites.					
6			Azacitidine 75mg/m ²	mg	SC	Slow push. If > 4mL split dose & inject at 2 separate sites.					
7			Azacitidine 75mg/m ²	mg	SC	Slow push. If > 4mL split dose & inject at 2 separate sites.					

- Azacitidine is to be given on **week days only**, not weekends or public holidays.
- Doses > 4mL should be equally divided into 2 syringes and injected into two separate sites. Rotate sites for injection (thigh, abdomen or upper arm).
- New injections should be given at least 2.5cm from an old site and never into areas where the site is tender, bruised, red or hard.
- Azacitidine is a cloudy solution. It must be administered at room temperature, however should not be out of the fridge for more than 30 minutes prior to administration.
- Re-suspend immediately prior to administration. To re-suspend, roll syringe vigorously between the palms until a uniform cloudy suspension is achieved. There must be no particles or clumping in the syringe. Inject slowly over 30-60 seconds
- Check CBC weekly with the first cycle of treatment then as indicated.
- Give allopurinol with first cycle and antifungal prophylaxis until haematological improvement.
- For information regarding delaying treatment for haematological toxicity please see red book.

Patient Category:
Y J A P O 1 3 Z

OSP Group:
1 2 3 4 5 6 7

Consultant:
NZMC Reg. No:

Special Authority

Authorised by: Dr S Gibbons
T:\Pictures\CDHB\Red_Book\MDS azacitidine chemo chart.doc

Pharmacist B Harden

February 2015
Review 2016

0 7 0 0 9 2 0

T H A R T

M E D - C A T - O N

Y H E M O T H E R A P Y